The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Dabigatran Association With Higher Risk of Acute Coronary Events: Meta-analysis of Noninferiority Randomized Controlled Trials
Abstract
BACKGROUND: The original RE-LY (Randomized Evaluation of Long-term Anticoagulant Therapy) trial suggested a small increased risk of myocardial infarction (MI) with the use of dabigatran etexilate vs warfarin in patients with atrial fibrillation. We systematically evaluated the risk of MI or acute coronary syndrome (ACS) with the use of dabigatran. METHODS: We searched PubMed, Scopus, and the Web of Science for randomized controlled trials of dabigatran that reported on MI or ACS as secondary outcomes. The fixed-effects Mantel-Haenszel (M-H) test was used to evaluate the effect of dabigatran on MI or ACS. We expressed the associations as odds ratios (ORs) and their 95% CIs. RESULTS: Seven trials were selected (N = 30,514), including 2 studies of stroke prophylaxis in atrial fibrillation, 1 in acute venous thromboembolism, 1 in ACS, and 3 of short-term prophylaxis of deep venous thrombosis. Control arms included warfarin, enoxaparin, or placebo administration. Dabigatran was significantly associated with a higher risk of MI or ACS than that seen with agents used in the control group (dabigatran, 237 of 20,000 [1.19%] vs control, 83 of 10,514 [0.79%]; OR(M-H), 1.33; 95% CI, 1.03-1.71; P = .03). The risk of MI or ACS was similar when using revised RE-LY trial results (OR(M-H), 1.27; 95% CI, 1.00-1.61; P = .05) or after exclusion of short-term trials (OR(M-H), 1.33; 95% CI, 1.03-1.72; P = .03). Risks were not heterogeneous for all analyses (I(2) = 0%; P ≥ .30) and were consistent using different methods and measures of association. CONCLUSIONS: Dabigatran is associated with an increased risk of MI or ACS in a broad spectrum of patients when tested against different controls. Clinicians should consider the potential of these serious harmful cardiovascular effects with use of dabigatran.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Universal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., White, H. D., TASK FORCE MEMBERS: Chairpersons: Kristian Thygesen (Denmark), J. S. A. (., Biomarker Group: Allan S. Jaffe, C. (., ECG Group: Bernard Chaitman, C.-O. (., Imaging Group: Richard Underwood, C. (., Intervention Group: Jean-Pierre Bassand, C.-O. (., Clinical Investigation Group: Paul W. Armstrong, C. (., Global Perspective Group: Philip A. Poole-Wilson, C. (., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.187397 · Cited by 4,230
Thygesen, K. A. (2007) · Circulation · Cited by 3,126
How should meta‐regression analyses be undertaken and interpreted?
Thompson, S. G., & Higgins, J. P. T. (2002) · Statistics in Medicine · doi:10.1002/sim.1187 · Cited by 3,026
Cited by
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,115
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Lip, G. Y. H., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P., ESC Committee for Practice Guidelines (CPG), et al. (2012) · EP Europace · doi:10.1093/europace/eus305 · Cited by 3,822
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.022 · Cited by 2,955
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Lip, G. Y. H., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P., ESC Committee for Practice Guidelines (CPG), et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs253 · Cited by 2,899
Meschia, J. F., Bushnell, C., Boden-Albala, B., Braun, L. T., Bravata, D. M., Chaturvedi, S., Creager, M. A., Eckel, R. H., Elkind, M. S. V., Fornage, M., et al. (2014) · Stroke · doi:10.1161/str.0000000000000046 · Cited by 2,650
Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H.-C., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., & Kirchhof, P. (2015) · Europace · doi:10.1093/europace/euv309 · Cited by 1,113
Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Schellong, S., Eriksson, H., Baanstra, D., Kvamme, A. M., Friedman, J., Mismetti, P., & Goldhaber, S. Z. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1113697 · Cited by 983
Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., & Kirchhof, P. (2013) · Europace · doi:10.1093/europace/eut083 · Cited by 792
National trends in ambulatory oral anticoagulant use
Barnes, G. D., Lucas, E., Alexander, G. C., & Goldberger, Z. D. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.05.044 · Cited by 598
Task Force Members, Lip, G. Y. H., Windecker, S., Huber, K., Kirchhof, P., Marin, F., Ten Berg, J. M., Haeusler, K. G., Boriani, G., Capodanno, D., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu298 · Cited by 566
Skanes, A. C., Healey, J. S., Cairns, J. A., Dorian, P., Gillis, A. M., McMurtry, M. S., Mitchell, L. B., Verma, A., & Nattel, S. (2012) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.01.021 · Cited by 494
Larsen, T. B., Rasmussen, L. H., Skjøth, F., Due, K. M., Callréus, T., Rosenzweig, M., & Lip, G. Y. H. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.03.020 · Cited by 403
Deep vein thrombosis: pathogenesis, diagnosis, and medical management
Stone, J., Hangge, P., Albadawi, H., Wallace, A., Shamoun, F., Knuttien, M. G., Naidu, S., & Oklu, R. (2017) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2017.09.01 · Cited by 381
Dentali, F., Riva, N., Crowther, M., Turpie, A. G. G., Lip, G. Y. H., & Ageno, W. (2012) · Circulation · doi:10.1161/circulationaha.112.115410 · Cited by 380
Hohnloser, S. H., Oldgren, J., Yang, S., Wallentin, L., Ezekowitz, M., Reilly, P., Eikelboom, J., Brueckmann, M., Yusuf, S., & Connolly, S. J. (2012) · Circulation · doi:10.1161/circulationaha.111.055970 · Cited by 348
Guidance for the treatment of deep vein thrombosis and pulmonary embolism
Streiff, M. B., Agnelli, G., Connors, J. M., Crowther, M., Eichinger, S., Lopes, R., McBane, R. D., Moll, S., & Ansell, J. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1317-0 · Cited by 344
National Trends in Oral Anticoagulant Use in the United States, 2007 to 2011
Kirley, K., Qato, D. M., Kornfield, R., Stafford, R. S., & Alexander, G. C. (2012) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.112.967299 · Cited by 311
Lip, G. Y. H., Larsen, T. B., Skjøth, F., & Rasmussen, L. H. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.019 · Cited by 288
Lamberts, M., Gislason, G. H., Lip, G. Y. H., Lassen, J. F., Olesen, J. B., Mikkelsen, A. P., Sørensen, R., Køber, L., Torp-Pedersen, C., & Hansen, M. L. (2014) · Circulation · doi:10.1161/circulationaha.113.004834 · Cited by 284
Furie, K. L., Goldstein, L. B., Albers, G. W., Khatri, P., Neyens, R., Turakhia, M. P., Turan, T. N., & Wood, K. A. (2012) · Stroke · doi:10.1161/str.0b013e318266722a · Cited by 270
Drug therapy in anticoagulation: which drug for which patient?
Millar, C. M., & Laffan, M. A. (2017) · Clinical Medicine · doi:10.7861/clinmedicine.17-3-233 · Cited by 11
Metadata
- Authors
- Uchino, K.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2012-03-12
- Volume
- 172
- Issue
- 5
- Pages
- 397
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2161876144
- Cited by
- 431
- References
- 26
- FWCI
- 65.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.